Prognostic Value of MammaPrint<sup>®</sup> in Invasive Lobular Breast Cancer

Beumer, Inès J.; Persoon, Marion; Witteveen, Anke; Dreezen, C; Chin, Suet-Feung; Sammut, Stephen‐John; Snel, Mireille H.J.; Caldas, Carlos; Linn, Sabine C.; Veer, Laura J. van ’t; Bernards, René; Glas, Annuska M.

doi:10.4137/bmi.s38435

Cited by 37 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Clinicopathologic parameters associated with lobular BC and their prognostic implications are partly controversial. [19][20][21][22][23][24][25][26] In the current retrospective, exploratory subgroup analysis, we evaluated lobular BCs that were included in the PlanB trial, a large, prospective, multicenter phase 3 trial encompassing >2500 HR-positive/HER2-negative BCs. [30][31][32] Lobular BCs accounted for 14% of cases, as determined by central histology review.…”

Section: Discussionmentioning

confidence: 99%

“…Lobular BC was associated with low and intermediate RS (P < .001) ( Table 2). Low RS (range, 0-11), intermediate RS (range, [12][13][14][15][16][17][18][19][20][21][22][23][24][25], and high RS (range, 26-100) Oncotype DX categories were observed in 20%, 72%, and 8% lobular BCs, respectively. The prevalence of high RS results was 3-fold lower in lobular BC compared with nonlobular BC (8% vs 24%; P < .001).…”

Section: Lower Rs In Lobular Bcmentioning

confidence: 98%

See 1 more Smart Citation

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Christgen

Gluz

Harbeck

et al. 2020

Cancer

View full text Add to dashboard Cite

BACKGROUND: Invasive lobular breast cancer (BC) is the second most common BC subtype. Prognostic parameters (tumor classification, lymph node status, histologic grade, Oncotype DX recurrence score [RS], progesterone receptor status, and Ki67 index) were retrospectively studied in a large, prospective clinical trial encompassing 2585 patients who had hormone receptor-positive early BC (the West German Study Group PlanB trial). METHODS: BCs were centrally reviewed and classified as lobular (n = 353; 14%) or nonlobular (n = 2232; 86%). The median follow-up was 60 months. Five-year disease-free survival (DFS) estimates were obtained using the Kaplan-Meier method. Prognostic parameters were evaluated using Cox proportional hazard models. RESULTS: Lobular BC was associated with higher tumor classification, higher lymph node status, lower histologic grade, lower Ki67 index, and low or intermediate RS. The prevalence of high RS (RS range, 26-100) was 3-fold lower in patients who had lobular BC compared with those who had nonlobular BC (8% vs 24%; P < .001). However, 5-year DFS estimates for lobular and nonlobular BC were similar (92.1% and 92.3%, respectively; P = .673). In multivariate analyses, prognostic parameters for DFS in lobular BC included grade 3 (hazard ratio, 5.06; 95% CI, 1.91-13.39) and a pathologic lymph node status (pN) of pN3 (

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Lower Rs In Lobular Bcmentioning

confidence: 98%

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Christgen

Gluz

Harbeck

et al. 2020

Cancer

View full text Add to dashboard Cite

show abstract

“…From our previous studies of gene expression in primary breast carcinomas, almost 100 genes of interest have been identified whose expression we have been identified using expression levels validated by qPCR using intact tissue sections from fresh frozen biopsies. Relationships between expression of candidate cancer‐related genes and protein biomarker content were analyzed through construction of violin plots (Figure ).…”

Section: Resultsmentioning

confidence: 99%

“…Genomic screens (eg, gene expression profiles) have been developed, which assess expression levels for genes whose actions and protein products are associated with breast cancer behavior. For instance, an FDA‐approved microarray test known as MammaPrint™ uses expression of 70 genes to assess risk of breast cancer development and risk of recurrence (website: https://www.agendia.com/our-tests/mammaprint/).…”

Section: Introductionmentioning

confidence: 99%

Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas

Sereff

Daniels

Wittliff

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background uPA, its receptor uPAR, and inhibitors PAI‐1 and PAI‐2 play key roles in membrane remodeling/invasion and in predicting response to chemotherapy. We identified novel relationships of these biomarkers with ER/PR that indicate clinical utility for assessing breast carcinoma outcomes. Methods Retrospective studies were performed with de‐identified results of (a) uPA, uPAR, and PAI‐1; (b) estrogen (ER) and progestin receptor (PR); and (c) clinical outcomes. Relative expression of 22 000 genes from microarray of RNA from LCM‐procured breast cancer cells was used with R Studio version 3.4.1. Results Primary ER/PR status was related to uPA, uPAR, or PAI‐1 levels. ER− or PR− cancers expressed elevated uPA, uPAR, and PAI2 mRNA compared to ER+ or PR+ cells. Inverse relationships between ER/PR protein and expression of uPA, uPAR, and PAI‐2 were observed, whereas HER2 status was unrelated. qPCR analyses showed RERG and NQO‐1 expressions were elevated in uPA− lesions, while CD34 and EDG‐1 were elevated in uPAR− cancers. ERBB4 was overexpressed in PAI‐1+ carcinomas. Cox regression analyses revealed relationships of ER/PR status and uPA system members with regard to clinical outcomes of breast cancer. Conclusions uPA, uPAR, PAI1, or PAI2 expression was increased in either ER− or PR− cancers similar to that of protein content in ER−/PR− carcinomas, suggesting sex hormones regulate the uPA system in breast cancer. Results revealed protein content of uPA system members was related to ER/PR status of primary lesions. Use of LCM‐procured carcinoma cells uncovered relationships between expression of known cancer−associated genes and protein content of uPA system members. Collectively, results indicate evaluation of ER and PR protein of primary breast cancers combined with analyses of uPA, uPAR, and PAI‐1 protein content improves assessment of clinical outcomes.

show abstract

“…and (C) immunohistopathological examinations [4]. Employing all these tools, the clinical oncologist can stage the disease using TNM classification [5] and reviewing the guidelines established in rigorous clinical trials, although, they can also use genetic profiling tests such as MammaPrint [6] and Oncotype DX [7] to understand disease prognosis better.…”

Section: Introductionmentioning

confidence: 99%

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Medina

Oza

Sharma

et al. 2020

IJERPH

224

164

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, and hence TNBC is managed with conventional therapeutics, often leading to systemic relapse. In terms of histology and transcription profile these cancers have similarities to BRCA-1-linked breast cancers, and it is hypothesized that BRCA1 pathway is non-functional in this type of breast cancer. In this review article, we discuss the different receptors expressed by TNBC as well as the diversity of different signaling pathways targeted by TNBC therapeutics, for example, Notch, Hedgehog, Wnt/b-Catenin as well as TGF-beta signaling pathways. Additionally, many epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors effectively inhibit the TNBCs, but they face challenges of either resistance to drugs or relapse. The resistance of TNBC to conventional therapeutic agents has helped in the advancement of advanced TNBC therapeutic approaches including hyperthermia, photodynamic therapy, as well as nanomedicine-based targeted therapeutics of drugs, miRNA, siRNA, and aptamers, which will also be discussed. Artificial intelligence is another tool that is presented to enhance the diagnosis of TNBC.

show abstract

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer

Cited by 37 publications

References 20 publications

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Contact Info

Product

Resources

About

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

Cited by 37 publications

References 20 publications

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Contact Info

Product

Resources

About

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer